Why AbbVie Stock Topped the Market Today

Core Insights - AbbVie reported strong quarterly earnings, with a net revenue of $13.3 billion, reflecting an 8% year-over-year increase, driven by a nearly 17% rise in immunology drug sales [2][3] - The company's stock gained over 3% following the earnings report, outperforming the S&P 500 index, which rose by 0.6% [1] - AbbVie raised its full-year profitability guidance, now expecting adjusted per-share earnings between $12.09 and $12.29, up from a previous range of $11.99 to $12.19 [5] Financial Performance - AbbVie's net revenue for Q1 was $13.3 billion, an 8% increase year-over-year, largely due to immunology drugs contributing nearly half of total revenue at just under $6.3 billion [2] - Non-GAAP adjusted net income decreased to $1.29 billion ($2.46 per share) from $1.37 billion in the previous year, slightly below analyst expectations of $2.39 per share [3] Management Commentary - CEO Robert Michael emphasized the strength of the company's fundamentals and the positive outlook bolstered by pipeline advancements and strategic investments, indicating AbbVie is well-positioned for long-term success [4]